Legend Biotech

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Legend Biotech surpasses Q2 sales targets, eyes market expansion

Legend Biotech's Q2 performance exceeded expectations with strong sales and positive study data.
The company's financial position is robust, with a healthy cash balance and plans for capacity expansion.
While facing challenges such as competitive pressures and operational optimizations, opportunities for growth exist.
Strategic initiatives focus on product quality, market expansion, and regulatory advancements for CARVYKTI.

Legend Biotech reports robust Q3 sales, eyes profitability targets

Legend Biotech's Q3 performance reflects strong sales driven by CARVYKTI, while maintaining a solid financial position with a focus on expansion.
The company faces challenges in achieving profitability targets and providing clarity on future sales projections.
Opportunities lie in pipeline advancements, collaboration partnerships, and innovative market expansion strategies.

Legend Biotech reports robust earnings, eyes expansion and regulatory milestones

Legend Biotech's strong earnings and cash balance provide stability and growth opportunities.
CARVYKTI's efficacy and convenience position it well, with plans for capacity expansion and partnerships.
Challenges include regulatory scrutiny and the need for clarity on future manufacturing scale-up.
Opportunities lie in extending manufacturing capacity, pipeline advancements, and profitability projections by 2026.

Legend Biotech reports robust Q1 performance and accelerates CAR-T expansion

Legend Biotech's Q1 2024 showcased strong performance with significant revenue growth and expansion plans to meet rising demand.
While facing challenges like sequential sales decrease and increased expenses, the company is leveraging strengths in production capacity and market diversification.
Opportunities lie in regulatory engagements for accelerated approvals, efficient market penetration strategies, and financial flexibility for future growth.
Overall, Legend Biotech's strategic focus on CAR-T therapies positions it well for continued success and innovation in the biopharmaceutical industry.

Legend Biotech excels in Q2, eyes FDA approvals and growth

Legend Biotech's Q2 2024 performance reflects strong sales growth, regulatory milestones, and promising clinical data, positioning the company for future success.
With a solid financial position, expanded production capacity, and ongoing research initiatives, Legend Biotech demonstrates resilience and strategic foresight in a competitive market landscape.
While facing challenges such as political risks and profitability targets, the company remains focused on growth opportunities and value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

CRISPR Therapeutics

Madrigal Pharmaceuticals

Vaxcyte

Revolution Medicines

Ventyx Biosciences

Western Alliance Bancorporation

Where is the current bull market? All indications would be that it's in biotech!

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

Legend Biotech Corporation Sponsored ADR (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Legend Biotech Corporation Sponsored ADR (LEGN) Soars 19.6%: Is Further Upside Left in the Stock?

BeiGene

BioMarin Pharmaceutical

Incyte

argenx

Bio-Techne

United Therapeutics

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).

7 Biotech Stocks That Could Cure Your Portfolio Woes

Cancer drug Carvykti had $72 million in sales in the first quarter. Legend's revenues grew by 70% last year.

Why Shares of Legend Biotech Jumped Wednesday

Legend Biotech: Leaked EHA Abstract Shows Outstanding CARTITUDE-4 Results

Legend Biotech is staring down a $9.6 billion opportunity, an analyst said Wednesday as LEGN stock soared on positive cancer test results. The post Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit appeared first on Investor's Business Daily.

Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit

Moderna

We have seen a host of companies such as Moderna Inc and Legend Biotech Corp grow to join the major league of biotech companies. But how do you spot the rookie in the minors ready to make the step up and what are the red flags?

Moderna, Legend Biotech advanced to the major league from the minors. But how do you spot a rookie company ready to move to the ‘show'?

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Mythili Koneru, M.D., Ph.D. as the Company's Chief Medical Officer. In this role, Dr. Koneru will be responsible for overseeing the Company's clinical development and medical affairs programs. Dr.

Legend Biotech Announces Appointment of Chief Medical Officer

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the formation of a strategic advisory board and the appointments of Michel Vounatsos, former CEO of Biogen Inc., and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors. Mr. Vounatsos and Dr.

Legend Biotech Establishes Strategic Advisory Board

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its full year 2022 audited financial results. "2022 was a year of significant milestones for Legend Biotech, marked by the regulatory approvals of CARVYKTI® in the U.S., Europe, and Japan.

Legend Biotech Reports Full-Year 2022 Results and Recent Highlights

Roivant Sciences Ltd

Beam Therapeutics

Editas Medicine

Intellia Therapeutics

Ultragenyx Pharmaceutical

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird myriad therapeutic advancements. For patients, they represent hope for a positive outcome.

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that it received notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) on February 17, 2023 indicating that the Company has regained compliance with Nasdaq Listing Rules 5250(c)(2).

Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)

Legend Biotech and partner Johnson & Johnson announced positive topline results from the CARTITUDE-4 trial of Carvykti last week. Positive results were expected and the market was not impressed either as no data was mentioned in the press release.

Legend Biotech: CARTITUDE-4 Study A Success

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that CARTITUDE-4, the Phase 3 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint of showing a statistically significant improvement in progression-free survival (PFS) compared to standard therapy at the study's first pre-specified interim analysis. The study has been unblinded following the recommendation of an independent data monitoring committee.

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on January 6, 2023 indicating that the Company is not currently in compliance with Nasdaq's Listing Rules (the “Listing Rules”) due to the Company's failure to file an interim balance sheet and income statement as of and for the quarter ended June 30, 2022 on Form 6-K with the Securities and Exchange Commission (“SEC”) . Pursuant to Listing Rule 5250(c)(2), the Company was required to file such Form 6-K no later than six months following the end of the quarter ended June 30, 2022, or December 31, 2022 (the “Due Date”). As of the date of this press release, the Company has not yet filed the required Form 6-K. This delay in filing such Form 6-K has resulted from the Company's planned restatement of its audited financial statements as of and for the years ended December 31, 2021, December 31, 2020 and December 31, 2019 and unaudited interim financial information for the three months ended March 31, 2022, as previously reported by the Company on its Form 6-K dated October 20, 2022.

Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases today announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA.

Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that China's National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for ciltacabtagene autoleucel (cilta-cel).

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

Legend Biotech Corporation (NASDAQ:LEGN) told investors that the US regulator, the Food and Drug Administration (FDA), had green-lighted its investigational new drug (IND) application for the treatment of small cell lung cancer (SCLC). It means the clinical development can now proceed on LB2102, an investigational, antigen receptor T-cell (CAR-T) therapy, in a bid to treat adults with extensive stage SCLC.

Legend Biotech set for clinical development of potential treatment for small cell lung cancer after FDA approval

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech's Investigational New Drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC).

Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Bio's Carvykti has been approved and is selling well despite manufacturing issues. Analysts have set multibillion-dollar target peak sales for the product.

Legend Biotech: Label Expansions Necessary To Realize Carvykti's Potential

Legend Biotech's Carvykti was approved this year for the treatment of fourth and fifth-line-plus multiple myeloma. Carvykti is partnered with J&J, and the launch is off to a strong start despite supply challenges, thanks to the outstanding CARTITUDE-1 trial data.

Legend Biotech: Carvykti Can Exceed J&J's Peak Sales Guidance

Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 14.2%: Will It Continue to Soar?

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.

News for Legend Biotech Stock (LEGN)